CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib.

Lin ZhangHongcai YangShangkun NingZhijuan WuDianzhe WangHexin LiangChunni WangChang Xu

Published in: Cancer medicine (2024)

The CRAFITY score, utilizing C-reactive protein and alpha-fetoprotein values, emerges as a dependable and pragmatic instrument for forecasting the effectiveness of TACE plus lenvatinib in individuals with unresectable HCC. This scoring system holds the potential to assist oncologists in making informed clinical decisions.

Keyphrases

liver metastases
radiofrequency ablation
randomized controlled trial
systematic review
study protocol
locally advanced
clinical trial
human health
radiation therapy
palliative care